Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKesson
Colorcon
Baxter
Harvard Business School

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR MEBENDAZOLE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mebendazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00116493 ↗ Severe Anemia Treatment Trials, Pakistan Completed Aga Khan University Phase 3 2004-04-01 The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.
NCT00116493 ↗ Severe Anemia Treatment Trials, Pakistan Completed Johns Hopkins Bloomberg School of Public Health Phase 3 2004-04-01 The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.
NCT01050452 ↗ Safety and Efficacy of Drug Combinations Against Trichuris Trichiura Completed DBL -Institute for Health Research and Development N/A 2007-10-01 This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.
NCT01173562 ↗ A Safety Study of Mebendazole in Children 2 to 10 Years of Age Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2010-02-01 The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
NCT01314937 ↗ The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas Completed Asociacion Civil Selva Amazonica Phase 4 2011-09-01 Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
NCT01314937 ↗ The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas Completed Canadian Institutes of Health Research (CIHR) Phase 4 2011-09-01 Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
NCT01314937 ↗ The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas Completed McGill University Phase 4 2011-09-01 Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mebendazole

Condition Name

Condition Name for Mebendazole
Intervention Trials
Helminthiasis 3
Anaplastic Astrocytoma 2
Hookworm Infections 2
Anemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mebendazole
Intervention Trials
Helminthiasis 7
Infections 6
Infection 6
Hookworm Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mebendazole

Trials by Country

Trials by Country for Mebendazole
Location Trials
United States 4
Tanzania 4
Ethiopia 3
India 2
Egypt 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mebendazole
Location Trials
Maryland 2
Florida 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mebendazole

Clinical Trial Phase

Clinical Trial Phase for Mebendazole
Clinical Trial Phase Trials
Phase 4 9
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mebendazole
Clinical Trial Phase Trials
Completed 18
Recruiting 5
Unknown status 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mebendazole

Sponsor Name

Sponsor Name for Mebendazole
Sponsor Trials
University Ghent 3
Bill and Melinda Gates Foundation 3
Swiss Tropical & Public Health Institute 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mebendazole
Sponsor Trials
Other 81
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Colorcon
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.